Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India

Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?

Boehringer Ingelheim headquarters in Ingelheim, Germany
BI Builds on Jardiance Plans In India • Source: Boehringer Ingelheim (dieth+schröder-fotografie)

It’s been an eventful few quarters for Boehringer Ingelheim GmbH in India and the German multinational appears to be taking the general turbulence in its stride, dealing deftly with infringement activity and building momentum for star brands such as Jardiance (empagliflozin), recently approved in the country for heart failure across the full spectrum of ejection fraction.

Boehringer has over the recent past stopped a handful of Indian companies in their tracks, at least for now, on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia